Home » PathoGenetix Raises $4M in First Closing of Series B Financing

PathoGenetix Raises $4M in First Closing of Series B Financing

Aug 02, 2011
Premium

This article was originally published Aug. 1.

PathoGenetix has raised $4 million in the first closing of a Series B financing round and has received $9.5 million in commitments for the round from investors, the Woburn, Mass.-based company said this week.

Excel Venture Management led the financing, which also included CB Health Ventures, HealthCare Ventures, and other investors who participated in the firm's 2010 Series A financing round, during which it raised $1.3 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

What's Popular?

In Clinical Sequencing

  1. NIH All of Us Program Awards $28.6M to Three Genome Centers Led by Baylor, Broad, UW

  2. New Data Underscores Volatility of Variant Classification, Highlights Need for Regular Reanalysis

  3. Nanopore Sequencing Becomes More Portable to Enable Outbreak Surveillance in Field

    Premium

  4. Geisinger Exome Study IDs Breast Cancer Risk Variants That May Not Have Been Detected in Routine Care

  5. GeneCentric Licenses UNC Pancreatic Cancer Subtyping Tech

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.